Journal article
Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients
Behavioural neurology, Vol.2018, 5969137
10/31/2018
DOI: 10.1155/2018/5969137
PMCID: PMC6234441
PMID: 30515252
Abstract
Objective. To evaluate longitudinal cognitive/behavioral change over 12 months in participants enrolled in the ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS). Methods. We analyzed data from 294 ALS participants, 134 of whom were studied serially. Change over time was evaluated controlling for age, sex, symptom duration, education, race, and ethnicity. Using multiple regression, we evaluated associations among decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores, forced vital capacity (FVC), and cognitive/behavioral changes. Change in cognitive/behavioral subgroups was assessed using one-way analyses of covariance. Results. Participants with follow-up data had fewer baseline behavior problems compared to patients without follow-up data. We found significant worsening of behavior (ALS Cognitive Behavioral Screen (ALS CBS) behavioral scale, p<0.001; Frontal Behavioral Inventory-ALS (FBI-ALS) disinhibition subscale, p=0.044). Item analysis suggested change in frustration tolerance, insight, mental rigidity, and interests (p<0.05). Changes in ALSFRS-R correlated with the ALS CBS. Worsening disinhibition (FBI-ALS) did not correlate with ALSFRS-R, FVC, or disease duration. Conclusion. We did not detect cognitive change. Behavioral change was detected, and increased disinhibition was found among patients with abnormal baseline behavioral scores. Disinhibition changes did not correlate with disease duration or progression. Baseline behavioral problems were associated with advanced, rapidly progressive disease and study attrition.
Details
- Title: Subtitle
- Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients
- Creators
- Susan Woolley - Pacific MedicalRay Goetz - Columbia UniversityPam Factor-Litvak - Columbia UniversityJennifer Murphy - University of California, San FranciscoJonathan Hupf - ALS Research CenterCatherine Lomen-Hoerth - University of California, San FranciscoHoward Andrews - Columbia UniversityDaragh Heitzman - Texas NeurologyRichard Bedlack - Duke UniversityJonathan Katz - Pacific Medical (China)Richard Barohn - University of KansasEric Sorenson - Mayo Clinic Rochester, MNBjorn Oskarsson - Mayo Clinic Rochester, MNAmerico Fernandes Filho - University of Nebraska Medical CenterEdward Kasarskis - University of KentuckyTahseen Mozaffar - University of California, IrvineSharon Nations - The University of Texas at AustinAndrea Swenson - University of IowaAgnes Koczon-Jaremko - Hospital for Special CareGeorgia Christodoulou - ALS Research CenterHiroshi Mitsumoto - ALS Research Center
- Contributors
- Francesca Trojsi (Editor)
- Resource Type
- Journal article
- Publication Details
- Behavioural neurology, Vol.2018, 5969137
- DOI
- 10.1155/2018/5969137
- PMID
- 30515252
- PMCID
- PMC6234441
- NLM abbreviation
- Behav Neurol
- ISSN
- 0953-4180
- eISSN
- 1875-8584
- Publisher
- Hindawi
- Grant note
- Ultragenyx Pharmaceutical R01ES016348 / National Institute of Environmental Health Sciences Anthony Senerchia Jr. ALS Charitable Foundation U.S. Food and Drug Administration ISIS Genzyme Iron Horse Diagnostics Merz Pharmaceuticals NS049203 / National Institutes of Health Amicus BioMarin Pharmaceutical Amyotrophic Lateral Sclerosis Association Novartis Pharmaceuticals Corporation ALS Therapy Development Institute Muscular Dystrophy Association Alexion Pharmaceuticals Motor Neurone Disease Association North Carolina GlaxoSmithKline Foundation Grifols Biogen Idec MDA Wings Over Wall Street Cytokinetics Neuraltus Alnylam Pharmaceuticals BMS CSL Behring Questcor Pharmaceuticals
- Language
- English
- Date published
- 10/31/2018
- Academic Unit
- Neurology
- Record Identifier
- 9984302207302771
Metrics
25 Record Views